Skip to main content
. Author manuscript; available in PMC: 2009 Feb 24.
Published in final edited form as: Ann Allergy Asthma Immunol. 2008 Nov;101(5):482–487. doi: 10.1016/S1081-1206(10)60286-4

Figure 1.

Figure 1

Relationship in the baseline year between the type of short-acting acting β-agonist used and the average number of the following: oral corticosteroid fills (A), asthma-related emergency department visits (B), and asthma-related hospitalizations (C). Bars represent 95% confidence intervals for category means and P values represent the test for trend across short-acting β-agonist categories. Tests for overall significance across categories were similar, with P = .001, .001, and .64 for A, B, and C, respectively.